UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): December 13, 1995
THERAGENICS CORPORATION
(Exact Name of Registrant as Specified in its Charter)
Delaware
(State of Incorporation)
0-15443 58-1528626
(Commission File Number) (I.R.S. Employer Identification No.)
5325 Oakbrook Parkway, Norcross, Georgia 30093
(Address of Principal Executive Offices) (Zip Code)
(770) 381-8338
(Registrant's Telephone Number, Including Area Code)<PAGE>
<PAGE>
Item 5. Other Events
Theragenics Secures $5 Million Credit Facility
Theragenics Corporation ("Theragenics") in an agreement with Bank South
dated December 13, 1995, secured a Line of Credit Facility and Revolving
Credit Facility (the "Facility") totaling $5,000,000. Under the Facility,
$3,000,000 became immediately available to Theragenics upon signing and
an additional $2,000,000 will be available as early as December 31, 1995,
contingent on Theragenics meeting certain financial benchmarks. As of the
date of this filing, Theragenics favorably exceeds all of these benchmarks
by large margins. Provisions of the Facility limit the amount of annual
capital expenditures, the incurrence of additional debt and requires,
among other things, the maintenance of certain minimum financial ratios.
The Facility is in addition to a $2,100,000 term loan from Bank South
which has been in place since September 1994. Management plans to use
proceeds from the Facility to help finance Company growth and partially
fund the addition of a third and fourth cyclotron to Theragenics'
manufacturing facility.
<PAGE>
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
THERAGENICS CORPORATION
Bruce W. Smith
Secretary, Treasurer and
Chief Financial Officer
Dated: December 22, 1995
